Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Celldex Therapeutics, Inc. Director's Dealing 2007

Jan 8, 2007

31801_dirs_2007-01-08_66ca4206-4352-409d-aede-2100028eae15.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVANT IMMUNOTHERAPEUTICS INC (AVAN)
CIK: 0000744218
Period of Report: 2007-01-05

Reporting Person: RYAN UNA S (Director, President & CEO)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2007-01-05 Incentive Stock Option $1.355 A 50000 Acquired 2017-01-05 Common Stock (50000) Direct